Published in Antiviral Res on December 31, 1999
Vaccination to prevent varicella and shingles. J Clin Pathol (2001) 1.02
Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol (1994) 7.36
Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science (2010) 6.67
From marrow to brain: expression of neuronal phenotypes in adult mice. Science (2000) 6.53
Plasticity of the differentiated state. Science (1985) 6.19
Cytoplasmic activation of human nuclear genes in stable heterocaryons. Cell (1983) 5.71
Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med (1992) 3.91
A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med (1991) 3.78
Monitoring protein-protein interactions in intact eukaryotic cells by beta-galactosidase complementation. Proc Natl Acad Sci U S A (1997) 3.46
Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr (1981) 3.42
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother (1992) 3.31
Genetic complementation reveals a novel regulatory role for 3' untranslated regions in growth and differentiation. Cell (1993) 3.16
VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation (2000) 3.13
Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell (1988) 2.94
Isolation and characterization of human muscle cells. Proc Natl Acad Sci U S A (1981) 2.92
Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics (2001) 2.91
Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol (1995) 2.87
The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol (1992) 2.80
Tumor suppression by RNA from the 3' untranslated region of alpha-tropomyosin. Cell (1993) 2.64
Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med (1986) 2.63
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Varicella vaccine in pregnancy. BMJ (1996) 2.38
Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. J Virol (1997) 2.34
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med (1997) 2.24
The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A (1998) 2.22
Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature (1992) 2.22
Effect of cell history on response to helix-loop-helix family of myogenic regulators. Nature (1990) 2.21
VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell (1998) 2.17
Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science (1991) 2.16
Reliability of a history of previous varicella infection in adults. JAMA (1997) 2.13
Developmental progression of myosin gene expression in cultured muscle cells. Cell (1986) 2.00
Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med (1987) 1.99
Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology (2000) 1.99
Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med (1986) 1.94
Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis (2001) 1.90
Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 1.83
Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Neurology (1991) 1.83
Transcriptional control: rheostat converted to on/off switch. Mol Cell (2000) 1.82
How fixed is the differentiated state? Lessons from heterokaryons. Trends Genet (1989) 1.82
Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 1.81
Purification of mouse primary myoblasts based on alpha 7 integrin expression. Exp Cell Res (2001) 1.79
Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A (1983) 1.77
Localization of muscle gene products in nuclear domains. Nature (1989) 1.75
Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis (1986) 1.72
Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med (1988) 1.67
Reprogramming cell differentiation in the absence of DNA synthesis. Cell (1984) 1.66
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1996) 1.66
Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody. Infect Immun (1983) 1.65
5-Azacytidine permits gene activation in a previously noninducible cell type. Cell (1985) 1.64
Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol (1989) 1.64
The eggshell of insects: differentiation-specific proteins and the control of their synthesis and accumulation during development. Results Probl Cell Differ (1977) 1.56
Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. J Virol (2001) 1.55
Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci U S A (1996) 1.55
Migration of myoblasts across basal lamina during skeletal muscle development. Nature (1990) 1.53
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat Cell Mol Genet (1990) 1.52
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis (1992) 1.45
Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis (1991) 1.43
Immunoglobulins M and G to varicella-zoster virus measured by solid-phase radioimmunoassay: antibody responses to varicella and herpes zoster infections. J Clin Microbiol (1980) 1.41
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Three slow myosin heavy chains sequentially expressed in developing mammalian skeletal muscle. Dev Biol (1993) 1.40
Differential patterns of transcript accumulation during human myogenesis. Mol Cell Biol (1987) 1.39
Graded transcriptional response to different concentrations of a single transactivator. Proc Natl Acad Sci U S A (1998) 1.39
Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol (2001) 1.36
Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol (1988) 1.35
Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve (1997) 1.34
A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci U S A (2006) 1.33
Gene expression and cell fusion analyzed by lacZ complementation in mammalian cells. Proc Natl Acad Sci U S A (1996) 1.30
Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol (2000) 1.30
Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. J Infect Dis (1988) 1.29
IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol (1999) 1.28
The well-tempered vessel. Nat Med (2001) 1.27
Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis (1992) 1.26
Isolation of human myoblasts with the fluorescence-activated cell sorter. Exp Cell Res (1988) 1.24
Epidermal growth factor receptor dimerization monitored in live cells. Nat Biotechnol (2000) 1.23
Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J Immunol (1994) 1.23
Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J Virol (2008) 1.22
Muscle cell components dictate hepatocyte gene expression and the distribution of the Golgi apparatus in heterokaryons. Genes Dev (1988) 1.22
Expression of muscle genes in heterokaryons depends on gene dosage. J Cell Biol (1986) 1.21
Muscle-mediated gene therapy. N Engl J Med (1995) 1.20
High-efficiency retroviral infection of primary myoblasts. Somat Cell Mol Genet (1997) 1.19
Fusarium brain abscess. Case report. J Neurosurg (1983) 1.17
Use of polymerase chain reaction for successful identification of asymptomatic genital infection with herpes simplex virus in pregnant women at delivery. J Infect Dis (1990) 1.17
Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis (1983) 1.16
A method to codetect introduced genes and their products in gene therapy protocols. Nat Biotechnol (1996) 1.16
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15
1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology (1986) 1.15
Development of muscle fiber types in the prenatal rat hindlimb. Dev Biol (1990) 1.15
Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host. J Virol (2001) 1.15
Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 1.15
The fate of myoblasts following transplantation into mature muscle. Exp Cell Res (1995) 1.15
Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. Nat Genet (1998) 1.14
Fusion competence of myoblasts rendered genetically null for N-cadherin in culture. J Cell Biol (1997) 1.13